KALA Stock Overview
KALA BIO, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
KALA BIO, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.84 |
| 52 Week High | US$19.35 |
| 52 Week Low | US$5.10 |
| Beta | -1.84 |
| 1 Month Change | -11.19% |
| 3 Month Change | -18.82% |
| 1 Year Change | -56.39% |
| 3 Year Change | -98.21% |
| 5 Year Change | -98.16% |
| Change since IPO | -99.26% |
Recent News & Updates
Recent updates
Kala Pharmaceuticals to execute reverse stock split
Oct 20Kala Pharmaceuticals Q2 2022 Earnings Preview
Aug 10Staying Patient With Kala Pharmaceuticals
Aug 29The Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Analysts Have Been Trimming Their Sales Forecasts
Aug 10
Is Kala Pharmaceuticals (NASDAQ:KALA) Using Debt Sensibly?
Jul 07Is Kala Pharmaceuticals (NASDAQ:KALA) Using Debt Sensibly?
Apr 05Kala Pharmaceuticals, Inc. (NASDAQ:KALA): When Will It Breakeven?
Mar 08What Kind Of Investors Own Most Of Kala Pharmaceuticals, Inc. (NASDAQ:KALA)?
Feb 15How Many Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Shares Did Insiders Buy, In The Last Year?
Jan 25
If You Had Bought Kala Pharmaceuticals (NASDAQ:KALA) Stock A Year Ago, You Could Pocket A 77% Gain Today
Jan 04Kala Pharmaceuticals Should Have Limited Downside With Eysuvis Now Approved
Dec 23The Play On Kala Pharmaceuticals
Dec 17Is Kala Pharmaceuticals (NASDAQ:KALA) Using Too Much Debt?
Dec 14How Much Did Kala Pharmaceuticals' (NASDAQ:KALA) CEO Pocket Last Year?
Nov 26Shareholder Returns
| KALA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -7.0% | -4.2% | -3.7% |
| 1Y | -56.4% | -2.0% | 20.5% |
Return vs Industry: KALA underperformed the US Biotechs industry which returned -1.7% over the past year.
Return vs Market: KALA underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| KALA volatility | |
|---|---|
| KALA Average Weekly Movement | 7.6% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: KALA's share price has been volatile over the past 3 months.
Volatility Over Time: KALA's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 43 | Mark Iwicki | www.kalarx.com |
KALA BIO, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases. The company’s product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases.
KALA BIO, Inc. Fundamentals Summary
| KALA fundamental statistics | |
|---|---|
| Market cap | US$19.29m |
| Earnings (TTM) | -US$42.20m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.5x
P/E RatioIs KALA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KALA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$42.20m |
| Earnings | -US$42.20m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -14.98 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 455.6% |
How did KALA perform over the long term?
See historical performance and comparison